Acknowledgements & References

We are fortunate to have various experts that have contributed information to this website to educate and support individuals and their family members who may be at increased risk for hereditary cancer. Please see below for a list of our contributors and references.

Contributors

  • Deepti Babu, MS, CGC
    Certified Genetic Counselor
    Clinical Content Manager, Ambry Genetics
  • Joe Bartfay
    Software Engineer, Ambry Genetics
  • Michael Brammer
    CEO, Progeny
  • Jackie Connor, MA
    Communications Associate, Ambry Genetics
  • E. David Crawford, MD
    Professor of Surgery, Urology and Radiation Oncology
    Head, Urologic Oncology
    University of Colorado
    Anschutz Medical Campus
  • Charles Dunlop
    President and Chairman, Ambry Genetics
  • Gretchen Enright
    Chief Compliance Officer, Ambry Genetics
  • Carin Espenschied, MS, CGC
    Certified Genetic Counselor
    Cancer Research Specialist, Ambry Genetics
  • Kelly Fulk, MS, CGC
    Genetic Counselor
    Cancer Reporting, Ambry Genetics
  • Ted Hanik
    Post Production Supervisor, Ambry Genetics
  • Michelle Jackson, MS, CGC
    Certified Genetic Counselor
    HBOC Product Manager, Ambry Genetics
  • Mike Janicek, MD
    Gynecologic Oncologist
    Medical Director of Gynecologic Oncology at Scottsdale Healthcare Medical Center and the Genetic Risk Assessment Center at Virginia Piper Cancer Center
  • Kory Jasperson, MS, CGC
    Certified Genetic Counselor
    Medical Affairs, Ambry Genetics
  • Jamie L'Heureux, MS, CGC
    Genetic Counselor
    Progeny Genetics
  • Cynthia Lund
    Patient Advocate
  • Tara Namey, MS, CGC
    Certified Genetic Counselor
    Oncology Genetic Specialist, Ambry Genetics
  • Sean Orfila
    Software Engineer, Ambry Genetics
  • Selvi Palaniappan, MS, CGC
    Certified Genetic Counselor
    Oncology Genetic Specialist, Ambry Genetics
  • Laura Panos, MS, CGC
    Certified Genetic Counselor
    Director of Genetic Specialists, Ambry Genetics
  • Jessica Profato, MS, CGC
    Certified Genetic Counselor
    Product Manager, Hereditary Cancers, Ambry Genetics
  • Caleb Remington
    Software Engineering Manager, Ambry Genetics
  • Bill Rotter
    Patient Advocate
  • Layla Shahmirzadi, MS, LCGC
    Genetic Counselor
    Director of Marketing, Ambry Genetics
  • Robina Smith, MD
    Breast Surgeon
    Medical Director of Oncology, Ambry Genetics
  • Michael Squier
    Creative Director, Ambry Genetics
  • Melissa Yoon
    General Counsel, Ambry Genetics

References by Section

Know the Basics

Genetic Information Nondiscrimination Act. “Your GINA Resource.” 2015. Available at http://ginahelp.org.

National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology® – Genetic/Familial High-Risk Assessment: Breast and Ovarian. Version 1.2015. Available at www.nccn.org

National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology® – Genetic/Familial High-Risk Assessment: Colorectal. Version 2.2015. Available at www.nccn.org

About Breast Cancer

Surveillance, Epidemiology, and End Results Program. "SEER Cancer Statistics Factsheets: Breast Cancer." Available at http://seer.cancer.gov/

American Cancer Society. "Breast Cancer Facts & Figures 2013-2014." Atlanta: American Cancer Society, Inc. 2013. Available at www.cancer.org

Center for Disease Control Website. "CDC - Are There Different Kinds of Breast Cancer?" Available at www.cdc.gov

National Cancer Institute. Comprehensive Cancer Information. 2015. Available at http://cancer.gov

American Joint Committee on Cancer. "Breast Cancer Staging, 7th Edition." Available at www.cancerstaging.org

Hartman M, et al. Is breast cancer prognosis inherited? Breast Cancer Res. 2007;9(3):R39.

Lindström L, et al. Familial concordance in cancer survival: a Swedish Population-based Study. Lancet Oncology. 2007 Nov;8(11):1001-1006.

Verkooijen HM, et al. Breast cancer prognosis is inherited independently of patient, tumor and treatment characteristics. Int J Cancer. 2012 May 1;130(9):2103-10.

Shu XO, et al. Novel genetic markers of breast cancer survival identified by a genome-wide association study. Cancer Res. 2012 May 1;72(5):1182-9.

Azzato EM, et al. Effects of common germline genetic variation in cell cycle control genes on breast cancer survival: results from a population-based cohort. Breast Cancer Res. 2008;10(3):R47.

About Ovarian Cancer

Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin. 2015 Jan-Feb;65(1): 5-29.

American Cancer Society. "Ovarian Cancer." Available at www.cancer.org

National Cancer Institute. Comprehensive Cancer Information. 2015. Available at http://cancer.gov

Center for Disease Control. "CDC – Ovarian Cancer." Available at www.cdc.gov/cancer/ovarian/

Ovarian Cancer Research Fund. "Staging and Grading." Available at www.ocrf.org/about-ovarian-cancer/treatment-of-ovarian-cancer/staging-and-grading

Society of Gynecologic Oncology. "SGO Clinical Practice Statement: Genetic Testing for Ovarian Cancer." October 2014. Available at www.sgo.org

Walsh T, et al. Mutations in 12 genes for inherited ovarian, fallopian tube, and peritoneal carcinoma identified by massively parallel sequencing. Proc Natl Acad Sci USA. 2011 Nov 1;108(44):18032-7.

Castera L, et al. Next-generation sequencing for the diagnosis of hereditary breast and ovarian cancer using genomic capture targeting multiple candidate genes. Eur J Hum Genet. 2014 Nov;22(11):1305-13.

Staples J and Goodman A. (2013). "PARP Inhibitors in Ovarian Cancer" in Ovarian Cancer - A Clinical and Translational Update. Dr. Ivan Diaz-Padilla (Ed.), ISBN: 978-953-51-1030-9, InTech, DOI: 10.5772/52888.

Guillem J, et al. ASCO/SSO review of current role of risk-reducing surgery in common hereditary cancer syndromes. J Clin Oncol. 2006 Oct 1; 24(28):4642-60.

National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology® – Genetic/Familial High-Risk Assessment: Breast and Ovarian. Version 1.2015. Available at www.nccn.org

Kaufman B, et al. Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation. J Clin Oncol. 2015 Jan 20;33(3):244-250.

Ledermann J, et al. Olaparib maintenance therapy in patients with platinum sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomized phase 2 trial. Lancet Oncol. 2014 Jul;15(8):852-61.

Ledermann J, et al. Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. N Engl J Med. 2012 Apr 12;366(15):1382-92.

About Colorectal Cancer

United States of America Congressional Record 111th Congress, Vol. 155- Part 7 (pg. 9086)

Surveillance, Epidemiology, and End Results Program. “SEER Stat Fact Sheets: Colon and Rectum Cancer.” Available at http://seer.cancer.gov/statfacts/html/colorect.html

American Cancer Society. “Learn About Cancer: Key statistics for colorectal cancer.” Available at www.cancer.org/cancer/colonandrectumcancer/detailedguide/colorectal-cancer-key-statistics

American Cancer Society. “Colorectal Cancer Risk Factors.” Available at www.cancer.org/cancer/colonandrectumcancer/detailedguide/colorectal-cancer-risk-factors

American Cancer Society. “Menopausal Hormone Therapy and Cancer Risk.” Available at www.cancer.org/cancer/cancercauses/othercarcinogens/medicaltreatments/menopausal-hormone-replacement-therapy-and-cancer-risk

American Cancer Society. “What are the Risk Factors for Endometrial Cancer?” Available at www.cancer.org/cancer/endometrialcancer/detailedguide/endometrial-uterine-cancer-risk-factors

Newcomb PA and Trentham-Dietz A. Breast feeding practices in relation to endometrial cancer risk, USA. Cancer Causes Control. 2000 Aug;11(7):663-7.

Women’s Health Initiative. “Questions and Answers about the WHI Postmenopausal Hormone Therapy Trials.” Available at www.nhlbi.nih.gov/whi/whi_faq.htm

Nichols HB, et al. Oral contraceptive use, reproductive factors, and colorectal cancer risk: findings from Wisconsin. Cancer Epidemiol Biomarkers Prev. 2005 May;14(5):1212-8.

Fernandez E, et al. Oral contraceptive use and risk of colorectal cancer. Epidemiology. 1998 May;9(3):295-300.

Newschaffer CJ, et al. Risk of colorectal cancer after breast cancer. Lancet. 2001 Mar 17:357(9259):837-40.

National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology® – Genetic/Familial High-Risk Assessment: Colorectal. Version 2.2015. Available at www.nccn.org

You Haven't Had Cancer

National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology® – Genetic/Familial High-Risk Assessment: Breast and Ovarian. Version 1.2015. Available at www.nccn.org

National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology® – Genetic/Familial High-Risk Assessment: Colorectal. Version 2.2015. Available at www.nccn.org

American Cancer Society. Available at www.cancer.org

Center for Disease Control Website. "CDC – What Are the Risk Factors for Breast Cancer?" Available at www.cdc.gov.

National Cancer Institute. Comprehensive Cancer Information. 2015. Available at http://cancer.gov

American Cancer Society. "Ovarian Cancer." Available at www.cancer.org.

American Cancer Society. “Colorectal Cancer Risk Factors.” Available at www.cancer.org/cancer/colonandrectumcancer/detailedguide/colorectal-cancer-risk-factors

American Cancer Society. “Menopausal Hormone Therapy and Cancer Risk.” Available at www.cancer.org/cancer/cancercauses/othercarcinogens/medicaltreatments/menopausal-hormone-replacement-therapy-and-cancer-risk

American Cancer Society “What are the Risk Factors for Endometrial Cancer?” Available at www.cancer.org/cancer/endometrialcancer/detailedguide/endometrial-uterine-cancer-risk-factors

Newcomb PA and Trentham-Dietz A. Breast feeding practices in relation to endometrial cancer risk, USA. Cancer Causes Control. 2000 Aug;11(7):663-7.

Women’s Health Initiative. “Questions and Answers about the WHI Postmenopausal Hormone Therapy Trials.” Available at www.nhlbi.nih.gov/whi/whi_faq.htm

Nichols HB, et al. Oral contraceptive use, reproductive factors, and colorectal cancer risk: findings from Wisconsin. Cancer Epidemiol Biomarkers Prev. 2005 May;14(5):1212-8.

Fernandez E, et al. Oral contraceptive use and risk of colorectal cancer. Epidemiology. 1998 May;9(3):295-300.

Newschaffer CJ, et al. Risk of colorectal cancer after breast cancer. Lancet. 2001 Mar 17:357(9259):837-40.